LEO Pharma receives positive CHMP opinion of Adtralza
Therapy is for the treatment of adolescents with moderate-to-severe atopic dermatitis
Read More
Tag: Adtralza
NICE recommend’s use of Leo Pharma’s Adtralza
The therapy is for moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic treatment
Read More
Roche’s Enspryng leads latest CHMP recommendations
CHMP adopted positive opinions for eight new medicines in its April meeting
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
